Exploration of the Potential Mechanism of Yiwei Decoction in the Treatment of Type Ⅱ Diabetes Mellitus Based on GEO Gene Chip, Network Pharmacology and Molecular Docking Technology

Objective To explore the potential mechanism of Yiwei decoction in treating T2DM by using GEO gene chip data combined with network pharmacology and molecular docking technology, and to provide reference for further basic research. Methods The active components and targets of yiwei decoction were screened from databases of TCMSP and BATMAN-TCM based on oral availability and Drug-like properties , we combined GeneCards, OMIM, Pharmgkb, TTD and DrugBank to search the target genes of T2DM. The software cytoscape 3.7.2 constructed the drug-component-target gene network to screen the core compounds The protein interaction analysis network was established by using String database, and the core protein targets were selected by cytoscape 3.7.2 topology analysis. Gene ontology (GO) function and KEGG (KEGG) pathway enrichment were analyzed using Metascape database, and molecular docking was visualized using autodock 3.7.2 and PyMol 2.1.1. Results 7577 targets of T2DM were selected, 38 active components of Yiwei decoction were identified, and the core components were γ-aminobutyric acid, quercetin, Kaempferol, β-sitosterol, etc. 191 potential effective targets were predicted, which involved PI3K-Akt, MAPK, HIF-1, RAP1, JAK-STAT and other pathways to treat T2DM. The chemical binding energy of EFGR, PPARG and ILIB to the active components was lower than -8 kcal/mol. Conclusion The active components of yiwei decoction may bind to EFGR, PPARG, ILIB and regulate HIF-1, MAPK, PI3K-Akt signal pathway to treat T2DM.